AbelZeta Pharma is a clinical-stage biopharmaceutical company that specializes in the development of innovative T-cell-based therapeutics aimed at treating various forms of cancer and inflammatory and immunological diseases. The company focuses on harnessing its research and development capabilities to create effective therapeutic products, particularly targeting hematologic malignancies and solid tumors. Their approach emphasizes the empowerment of the immune system, offering personalized treatment options that enhance the body's natural defenses against these diseases.

The core technologies utilized by AbelZeta include Chimeric Antigen Receptor T-cell (CAR-T) therapy and Tumor Infiltrating Lymphocytes (TIL) therapy. CAR-T therapy involves engineering a patient's T cells to express receptors that specifically target cancer cells, thereby improving the immune response against tumors. TIL therapy, on the other hand, involves isolating and expanding T cells that have already infiltrated a tumor, which can then be reinfused into the patient to bolster the immune attack on the cancer. Together, these technologies represent a cutting-edge approach to immunotherapy, aiming to provide more effective and personalized treatment options for patients suffering from cancer and inflammatory diseases.

United States

AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body's own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T and TIL therapies. 

AbelZeta

Company Details